IL6 and autosomal dominant polycystic kidney disease: Our data demonstrated no differences in markers of inflammation (i.e., IL-6 and TNF-α), as previously described in some series from initial stages of the disease.63, , , , –68 Serum level of ADMA, an important inhibitor of nitric oxide synthase, was also not different between ADPKD and controls, in contrast to findings in the literature.69, –71 Similarly, in a previous study from our group,72 basal ADMA levels were not altered in young normotensive patients with ADPKD versus controls.